Cardinal Health 414, LLC

Cardinal Health 414, LLC (Nphs Division, doing business as Cardinal Health 414, Inc.), a subsidiary of Cardinal Health, Inc. headquartered in Dublin, Ohio, manufactures, tests, and distributes radiopharmaceuticals and medical isotopes to federal healthcare agencies as a prime contractor operating on an unrestricted, full-and-open competition basis with no set-aside designations.

Cardinal Health 414 occupies a specialized niche in federal procurement: single-source supplier of proprietary radiopharmaceutical products for nuclear medicine and diagnostic imaging across the VA and Defense Health Agency. The company's portfolio spans standard diagnostic agents—technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, fluorine-18 fluorodeoxyglucose (FDG), and gallium-67—as well as exclusive-rights therapeutics including Xofigo (radium-223 dichloride) for prostate cancer treatment and Lymphoseek for lymph node imaging. The company holds Nuclear Regulatory Commission licensing and FDA approvals for radiopharmaceutical manufacturing and maintains Department of Transportation compliance for radioactive materials transport, positioning it as a critical infrastructure supplier for time-sensitive medical isotope delivery—often one-to-one-and-a-half-hour turnaround requirements to accommodate short radioactive half-lives.

Recent federal footprint centers on the Department of Veterans Affairs across multiple Veterans Integrated Service Networks (VISNs) and the Defense Health Agency. The top five customers by combined potential value—VISN 8 ($356.4 million across 166 awards), VISN 22 ($126.7 million across 176 awards), Defense Health Agency ($72.8 million across 106 awards), VISN 9 ($59.9 million across 57 awards), and VISN 17 ($57 million across 72 awards)—represent 55 percent of combined potential value. Activity has remained steady: 96 awards in 2024, 96 in 2025, and 30 year-to-date in 2026, with $1.22 billion combined potential value across 4,746 prime awards (100 percent of footprint) and $385.7 million in obligated dollars.

Cardinal Health 414 operates exclusively through indefinite-delivery contracts and blanket purchase agreements with individual VISNs and the Defense Health Agency. Signature vehicles include single-award IDIQs with VISN 8 ($3.07 billion potential value, 166 awards through September 2025), VISN 22 ($1.49 billion potential value, 176 awards through March 2026), and a Defense Health Agency BPA ($7.5 million ceiling through September 2030). Delivery orders under these vehicles carry firm fixed-price terms, no set-asides, and performance from the Dublin, Ohio facility. Recent named awards include a $3.07 million delivery order to VISN 8 (October 2024, radiopharmaceuticals), a $1.49 million delivery order to VISN 22 (April 2024, radiopharmaceutical manufacturing and delivery), and a $1.32 million delivery order to VISN 21 (April 2025, radiopharmaceuticals). Many contracts specify expedited delivery: daily morning deliveries by 7:00 AM at no additional charge, with emergency response within one to two hours.

Recompete exposure concentrates in the next twenty-four months: 72 awards with combined potential value of $36.9 million reach ultimate completion through July 2028. Several vehicles approach renewal or expiration—VISN 15 and VISN 6 IDIQs mature in 2025–2026, while major VISN 8 and Defense Health Agency platforms extend through 2029–2030.

Cardinal Health 414's federal posture is entirely unrestricted and full-and-open; the company competes as a large, established healthcare manufacturer with proprietary product rights justifying sole-source awards under FAR 6.302-1 (only available source). No subcontractor teaming is evident in the footprint. The parent company, Cardinal Health, Inc., carries a broader federal profile across pharmaceutical distribution, medical supplies, and surgical instruments, but Cardinal Health 414 operates as a distinct radiopharmaceutical manufacturing and supply entity tied exclusively to nuclear medicine and diagnostic imaging markets.